Bendamustine

Drugs

Volumn 61, Issue 5, 2001, Pages 631-638

  Barman Balfour, Julia A ^a   Goa, Karen L ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

BENDAMUSTINE; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; FLUOROURACIL; MELPHALAN; METHOTREXATE; PREDNISOLONE; PREDNISONE;

ALOPECIA; BLOOD TOXICITY; BREAST CANCER; CLINICAL TRIAL; DRUG CROSS REACTIVITY; DRUG MECHANISM; DRUG TOLERABILITY; GASTROINTESTINAL SYMPTOM; HODGKIN DISEASE; HUMAN; META ANALYSIS; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; OVARY CANCER; REVIEW;

EID: 0034995976     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200161050-00009     Document Type: Review

References (37)

1. 1. Ribosepharm GmbH. Bendamustine product monograph. München, Germany, 2000
2. 2. Bremer K, Roth W. Bendamustine, a low toxic nitrogen-mustard derivative with high efficacy in malignant lymphomas. Tumor Diagn Ther 1996; 17 (1): 1-6
3. 3. Strumberg D, Harstrick A, Doll K, et al. Bendamustine hydrochloride activity against doxorubicin-resistant human breast carcinoma cell lines. Anticancer Drugs 1996 Jun; 7: 415-21
4. 4. Schwaenen C, Karakas T, Schrader M. Bendamustin in induction of apoptosis in B-cell chronic lymphocytic leukemia [abstract]. Ann Oncol 1999; 10 Suppl. 3: 132
5. 5. Schöffski P, Seeland G, Engel H, et al. Weekly administration of bendamustine; a phase I study in patients with advanced progressive solid tumours. Ann Oncol 2000 Jun; 11: 729-34
6. 6. Kath R, Blumenstengel K, Fricke HJ, et al. Bendamustine monotherapy in advanced and refractory chronic lymphocytic leukemia. J Cancer Res Clin Oncol 2001; 127: 48-54
7. 7. Matthias M, Preiss R, Sohr R, et al. Pharmacokinetics of bendamustine in patients with malignant tumors [abstract]. Proc Am Soc Clin Oncol 1995 Mar; 14: 458
8. 8. Haase D, Preiss R, Sohr R. Untersuchungen zur Plasmaeiweiβbindung von Bendamustin (Cytostasan) und Ambazon. Z Klin Med 1990; 45: 1267-72
9. 9. Preiss R, Sohr R, Matthias M, et al. Pharmacokinetics of bendamustine (Cytostasane) in patients [in German]. Pharmazie 1985 Nov; 40: 782-4
10. 10. Herold M, Schulze A, Mantovani L, et al. BOP versus COP in advanced low grade non-Hodgkin's lymphomas - results of a randomized multicenter study [abstract]. Blood 1999 Nov 15; 94 Suppl. 1 (Pt 2): 262
11. 11. Pönisch W. Mitrou PS, Merkle K, et al. A randomized multicenter study of bendamustine/prednisone versus melphalane/ prednisone in the primary treatment of multiple myeloma [abstract no. 542]. Blood 1999; 94 (10) Suppl. 1: 123a
12. 12. Poenisch W, Mitrou PS, Merkle KH, et al. Bendamustine/prednisone versus melphalan/prednisone in the primary treatment of multiple myeloma: an updated analysis of the 94BP01 protocol [abstract]. Blood 2000 Nov 16; 96 Suppl. 11 (Pt 1): 759a
13. 13. Ruffert K, Jahn H, Syrbe G, et al. Cytostasan (Bendamustin) in der Alternativetherapie maligner Non-Hodgkin-Lymphome [in German]. Z Klin Med 1989; 44: 671-4
14. 14. Blumenstengel K, Fricke H-J, Kath R, et al. Bendamustin (B), vincristin (O), prednisolon (P) in relapsed and refractory low-grade non-Hodgkin-lymphomas (NHL) [abstract no. 591]. Ann Hematol 1999; 77 Suppl. II: S149
15. 15. Gnad M, Reichle A, Andreesen R, et al. Therapy of low-grade non-Hodgkin's-lymphoma (NHL) with fludarabine and bendamustine [abstract]. Onkologie 1999 Aug; 22 Suppl. 1: 168
16. 16. Ruffert K. Therapy of low grade non-Hodgkins-lymphoma (NHL) with bendamustine and oral etoposide [abstract no. 452]. Ann Oncol 1999; 10 Suppl. 5: 125
17. 17. König U, Junghauss C, Decker S, et al. Response of refractory and relapsed low grade non-Hodgkin's lymphoma and chronic lymphocytic leukemia to Dexa-BID, a bendamustine hydrochloride containing regimen [abstract no. 479]. Ann Oncoll 1999; 10 Suppl. 3: 132
18. 18. Heider A, Kress M, Niederle N. Relapse therapy with bendamustine in patients with low grade non Hodgkin lymphomas (NHL): efficacy and toxicity [abstract]. Blood 1998 Nov 15 Suppl. 1 (Pt 2): 236
19. 19. Heider A, Kress M, Niederle N. Bendamustin as second-line therapy in patients with relapsed low grade non-Hodgkin's lymphoma and multiple myeloma [in German]. Tumor Diagn Ther 1997; 18: 71-5
20. 20. Preiss J, Heck HK, Schmidt P. Bendamustine in the therapy of low-grade malignant lymphomas [abstract]. Eur J Cancer 1999 Sep; 35 Suppl. 4: 336
21. 21. Kahl C, Herold M, Höffkes HG, et al. Bendamustine, methotrexate, mitoxantrone, and prednisolone (BMMP) for the treatment of relapsed or refractory high-grade non-Hodgkin's lymphoma. Onkologie 1997; 20 (5): 406-8
22. 22. Weidmann E, Kim ZC, Geduldig K, et al. Palliative treatment of high grade non Hodgkin's lymphoma with bendamustine: a phase II study [abstract]. Onkologie 2000; 23 (Sonderheft 7): X210
23. 23. Herold M, Keinert K, Anger G, et al. Risk-adapted combined radiotherapy and chemotherapy for Hodgkin's disease - results of a pilot study. Onkologie 1992; 15: 502-5
24. 24. Herold M, Keinert K, Anger G. Risk adapted combined radio-and chemotherapy in Hodgkin's disease - 10-year follow-up. Onkologie 1999; 22 (4): 310-3
25. 25. Herold M, Siebert S, Schulze A, et al. Reduced combined modality treatment for Hodgkin's disease: results of a randomized multicenter trial [abstract no. P-85]. Leuk Lymphoma 1998; 29 Suppl. 1
26. 26. Aivado M, Becker K, Neise M, et al. Bendamustine (B) is an efficient and well-tolerated option in the palliation of pre-treated B-cell chronic lymphocytic leukemias (CLL) [poster]. 37th Annual Meeting of the American Society of Clinical Oncology (ASCO); 2001 May 12-15; San Francisco (CA)
27. 27. Ruffert K. Primary chemotherapy of metastatic breast carcinoma with bendamustine hydrochloride, methotrexate and fluorouracil versus cyclophosphamide, methotrexate and fluorouracil [in German]. Zentralbl Chir 1998; 123 Suppl. 5: 156-8
28. 28. Höffken K, Merkle K, Schönfelder M, et al. Bendamustine as salvage treatment in patients with advanced progressive breast cancer: a phase II study. J Cancer Res Clin Oncol 1998; 124: 627-32
29. 29. Jamitzky T, Lange OF. Third-line chemotherapy with bendamustin for metastatic breast cancer - a prospective pilot study [abstract]. Eur J Cancer A 1996; 32A Suppl. 2: 47
30. 30. Schmidt P, Heck HK, Preiss J. Bendamustin/mitoxantrone in the treatment of advanced breast cancer [abstract]. Eur J Cancer 1999 Sep; 35 Suppl. 4: 324
31. 31. Heider A, Köster W, Grote-Kiehn J, et al. Bendamustin in untreated small cell lung cancer (SCLC): efficacy and toxicity [abstract]. Eur J Cancer 1999 Sep; 35 Suppl. 4: 254
32. 32. Reck M, Haering B. Koschel G, et al. Chemotherapy of advanced SCLC and NSCLC with bendamustine - a phase II study [in German]. Pneumologie 1998 Oct; 52: 570-3
33. 33. Schilcher RB, Rahn A, Haase KD. Recurrent ENT tumors treated with bendamustine or gemcitabine and radiotherapy. 36th Proc Am Soc Clin Oncol, New Orleans, 20-23 May 2000; 19: 426
34. 34. Ridwelski K, Rudolph St, Fahlke J, et al. Combination bendamustin (B), mitomycin (M), 5-FU (FU) and prednisolon (P) in advanced gastrointestinal tumours with progress under chemotherapy [abstract]. Eur J Cancer A 1997 Sep; 33 Suppl. 8: 283
35. 35. Kollmannsberger C, Gerl A, Schleucher N, et al. Phase II study of bendamustine in patients with relapsed or cisplatin-refractory germ cell cancer. Anticancer Drugs 2000 Aug; 11: 535-9
36. 36. Von Minckwitz G, Souchon R, Kleeberg UR, et al. Bendamustin, MTX, 5-FU (BMF) vs. cyclophosphamide, MTX, 5-FU (CMF) as first line therapy of metastatic breast cancer: a safety interim analysis. 36th Annual Meeting of the American Society of Oncology; 2000 May 20-23; New Orleans (LA), 120
37. 37. Blumenstengel K, Schmalenberg H, Fricke H-J, et al. Bendamustin monotherapy in advanced and refractory chronic lymphocytic leukemia [abstract]. Onkologie 1997 Oct; 20 Suppl. 1: 143